Chemo tablets with or without an immune therapy after cancer treatment
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether taking the chemo tablet capecitabine after standard chemoradiation can help prevent cancer from coming back, and whether adding an immune therapy (a PD-1 antibody) improves results. It is for people with high-risk nasopharyngeal (throat) cancer whose main treatment has already finished.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 65 years old when diagnosed
- Have nasopharyngeal cancer confirmed by biopsy as a non-keratinizing type
- Have high-risk, locally advanced disease with no spread to distant organs after initial treatment
- Finish induction and chemoradiation, and start the study treatment within 1 month (no later than 6 weeks) after radiation ends
- Have good blood counts, liver, and kidney function (study lab thresholds will be checked)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding chemotherapy before the usual radiation and chemotherapy treatment can improve outcomes for people with a certain type of nasopharyngeal cancer that has higher risk features. It aims to see if the extra treatment helps control the cancer better.
This trial tests whether adding the immunotherapy drug toripalimab to the chemotherapy pill capecitabine after standard treatment helps prevent nasopharyngeal cancer from coming back. It is for people with high-risk features who have already had chemo and radiation.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
This study tests nituzumab (a targeted antibody) added to standard induction chemotherapy versus placebo plus chemotherapy. It aims to improve tumor control and safety for people with locally advanced nasopharyngeal (throat) cancer.
This trial compares two options—a type of immunotherapy or a chemotherapy pill (capecitabine)—as maintenance treatment after standard chemoradiation for high-risk nasopharyngeal cancer. It aims to see which helps prevent the cancer from coming back.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.